About
Tailored Antibody Optimization
CombinAble offers a revolutionary approach to therapeutic design. Its unique AI platform moves beyond standard antibodies, enabling the rapid in silico development of complex formats, including bi-specifics, tri-specifics, and T-cell engagers.
The platform enables development of best-in-class therapeutics in just 4 months—dramatically faster than traditional methods. This accelerated timeline, even for the most complex biologics, gives our partners a significant competitive advantage.
Identity
| Name | CombinAble.AI |
|---|---|
| Slug | combinable-ai |
| Type / kind | startup |
| Source _id | Axo4qAsfrAE9GcREGvJPzDMYe4S0EMH6ahMFWRP1rL3jwP3XD6258N |
Status
| Status | acquired |
|---|---|
| Status reason | Acquired by insitro on Jan 2026 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Rehovot |
| HQ address | Rehovot, Israel |
Web & social
| Website | https://combinableai.com/ |
|---|---|
| https://www.linkedin.com/company/100601708/ |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial Intelligence
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business models
B2B
Tags
drug-developmentartificial-intelligencebiopharmaceuticalbiotechnologytherapeuticspharmaceuticalsantibodies
Funding
| Total raised | — |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}